Company intelligence / Profile preview

Purple Agency

Rehovot, Israel

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Purple Biotech currently has two clinical-stage programs: CM24 (a monoclonal antibody against CEACAM1) in Phase 2 for metastatic pancreatic cancer (combination with nivolumab + chemotherapy, with positive proof-of-concept data), and NT219 (a small molecule dual IRS1/2 and STAT3 inhibitor) in Phase 1/2 for solid tumors and head and neck cancer with signals of anti-tumor activity; its newest platform, CAPTN-3, is preclinical.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodySmall moleculeTri-specific antibodyAntibodyAntibody-drug conjugate
Industry: Biotech

Partnerships

Bristol Myers Squibb (clinical collaboration for CM24/nivolumab)University of Colorado (for NT219 studies)

Beyond the preview

Go deeper on Purple Agency.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Purple Agency.

Explore the full profile